Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily, acting as potent regulators during embryogenesis and bone and cartilage formation and repair. Cell and molecular biology approaches have unveiled the great complexity of BMP action, later confirmed by transgenic animal studies. Genetic engineering allows for the production of large amounts of BMPs for clinical use, but they have systematically been associated with a delivery system, such as type I collagen and calcium phosphate ceramics, to ensure controlled release and to maximize their biological activity at the surgical site, avoiding systemic diffusion. Clinical orthopedic studies have shown the benefits of FDA-approved recombinant human BMPs (rhBMPs) 2 and 7, but side effects, such as swelling, seroma, and increased cancer risk, have been reported, probably due to high BMP dosage. Several studies have supported the use of BMPs in periodontal regeneration, sinus lift bone-grafting, and non-unions in oral surgery. However, the clinical use of BMPs is growing mainly in off-label applications, with robust evidence to ascertain rhBMPs’ safety and efficacy through well-designed, randomized, and double-blind clinical trials. Here we review and discuss the critical data on BMP structure, mechanisms of action, and possible clinical applications.
AltVDonellSTChhabraABentleyAEicherASchnettlerR (2009). A health economic analysis of the use of rhBMP-2 in Gustilo-Anderson grade III open tibial fractures for the UK, Germany, and France. Injury40:1269-1275.
2.
Ben-DavidDSroujiSShapira-SchweitzerKKossoverOIvanirEKuhnG. (2013). Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. Biomaterials34:2902-2910.
3.
BowersGFeltonFMiddletonCGlynnDSharpSMellonigJ. (1991). Histologic comparison of regeneration in human intrabony defects when osteogenin is combined with demineralized freeze-dried bone allograft and with purified bovine collagen. J Periodontol62:690-702.
4.
Bustos-ValenzuelaJCHalcsikEBassiEJDemasiMAGranjeiroJMSogayarMC (2010). Expression, purification, bioactivity, and partial characterization of a recombinant human bone morphogenetic protein-7 produced in human 293T cells. Mol Biotechnol46:118-126.
5.
Bustos-ValenzuelaJCFujitaAHalcsikEGranjeiroJMSogayarMC (2011). Unveiling novel genes upregulated by both rhBMP2 and rhBMP7 during early osteoblastic transdifferentiation of C2C12 cells. BMC Res Notes4:370.
6.
CahillKSChiJHDayAClausEB (2009). Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. J Am Med Assoc302:58-66.
7.
CestariTMGranjeiroJMde AssisGFGarletGPTagaR (2009). Bone repair and augmentation using block of sintered bovine-derived anorganic bone graft in cranial bone defect model. Clin Oral Implants Res20:340-350.
8.
ChenGDengCLiYP (2012). TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci8:272-288.
9.
ChrastilJLowJBWhangPGPatelAA (2013). Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine. Spine (Phila Pa 1976)38:E1020-E1027.
10.
ColinCDemasiMADegakiTLBustos-ValenzuelaJCFigueiraRCMontorWR. (2008). NUCEL (Cell and Molecular Therapy Center): a multidisciplinary center for translational research in Brazil. Mol Biotechnol39:89-95.
11.
DegatMCFerreiraELogeart-AvramoglouD (2005). Use of growth factors in the repair of bone. Pathol Biol (Paris)53:131-41.
12.
DeschaseauxFSensebeLHeymannD (2009). Mechanisms of bone repair and regeneration. Trends Mol Med15:417-429.
13.
DevineJGDettoriJRFranceJCBrodtEMcGuireRA (2012). The use of rhBMP in spine surgery: is there a cancer risk?Evid Based Spine Care J3:35-41.
14.
DucyPKarsentyG (2000). The family of bone morphogenetic proteins. Kidney Int57:2207-2214.
15.
DunnCAJinQTabaMJrFranceschiRTRutherfordRBGiannobileWV (2005). BMP gene delivery for alveolar bone engineering at dental implant defects. Mol Ther11:294-299.
16.
GarrisonKRShemiltIDonellSRyderJJMugfordMHarveyI. (2010). Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev6:CD006950.
17.
GerstenfeldLCCullinaneDMBarnesGLGravesDTEinhornTA (2003). Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem88:873-884.
18.
GiannobileWVSomermanMJ (2003). Growth and amelogenin-like factors in periodontal wound healing. A systematic review. Ann Periodontol8:193-204.
19.
GiannobileWVRyanSShihMSSuDLKaplanPLChanTC (1998). Recombinant human osteogenic protein-1 (OP-1) stimulates periodontal wound healing in class III furcation defects. J Periodontol69:129-137.
20.
GiannoudisPVTzioupisC (2005). Clinical applications of BMP-7: the UK perspective. Injury36(Suppl 3):47-50.
21.
GiannoudisPVKanakarisNKDimitriouRGillIKolimaralaVMontgomeryRJ (2009). The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions. Clin Orthop Relat Res467:3239-3248.
22.
GranjeiroJMOliveiraRCBustos-ValenzuelaJCSogayarMCTagaR (2005). Bone morphogenetic proteins: from structure to clinical use. Braz J Med Biol Res38:1463-1473.
23.
GranjeiroJMAlvesGGAntunesLCalasans-MaiaMDZambuzziWF (2010). Understanding the bone morphogenetic proteins: from structure to clinical applications. In: Uma Odontologia de Classe Mundial - FDI. FernandesC, editor. São Paulo, BR: Santos, pp. 109-140.
24.
GriffithDLKeckPCSampathTKRuegerDCCarlsonWD (1996). Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc Natl Acad Sci USA93:878-883.
25.
HagiTTWuGLiuYHunzikerEB (2010). Cell-mediated BMP-2 liberation promotes bone formation in a mechanically unstable implant environment. Bone46:1322-1327.
26.
HalcsikEForniMFFujitaAJensenONSogayarMC (2013). New insights in osteogenic differentiation revealed by mass spectrometric assessment of phosphorylated substrates in murine skin mesenchymal cells. BMC Cell Biol14:47.
27.
HongPBoydDBeyeaSDBezuhlyM (2013). Enhancement of bone consolidation in mandibular distraction osteogenesis: a contemporary review of experimental studies involving adjuvant therapies. J Plast Reconstr Aesthet Surg66:883-895.
28.
HusseinKAZakharyIEHailatDElrefaiRSharawyMElsalantyME (2013). Delayed versus immediate reconstruction of mandibular segmental defects using recombinant human bone morphogenetic protein 2/absorbable collagen sponge. J Oral Maxillofac Surg71:1107-1118.
29.
IshibashiOIkegameMTakizawaFYoshizawaTMoksedMAIizawaF. (2010). Endoglin is involved in BMP-2-induced osteogenic differentiation of periodontal ligament cells through a pathway independent of Smad-1/5/8 phosphorylation. J Cell Physiol222:465-473.
JohnsonEEUristMRFinermanGA (1992). Resistant nonunions and partial or complete segmental defects of long bones. Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. Clin Orthop Relat Res277:229-237.
32.
KamitakaharaMOhtsukiCMiyazakiT (2008). Review paper: behavior of ceramic biomaterials derived from tricalcium phosphate in physiological condition. J Biomater Appl23:197-212.
33.
LanJWangZWangYWangJChengX (2006). The effect of combination of recombinant human bone morphogenetic protein-2 and basic fibroblast growth factor or insulin-like growth factor-I on dental implant osseointegration by confocal laser scanning microscopy. J Periodontol77:357-363.
34.
LeknesKNYangJQahashMPolimeniGSusinCWikesjöUM (2008). Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-2: radiographic observations. Clin Oral Implants Res19:1027-1033.
35.
LiJHuangXXuXMayoJBringasPJrJiangR. (2011). SMAD4-mediated WNT signaling controls the fate of cranial neural crest cells during tooth morphogenesis. Development138:1977-1989.
36.
LiRHWozneyJM (2001). Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol19:255-265.
37.
Lissenberg-ThunnissenSNde GorterDJSierCFSchipperIB (2011). Use and efficacy of bone morphogenetic proteins in fracture healing. Int Orthop35:1271-1280.
38.
Lomelino RdeOCastro-SilvaIILinharesABAlvesGGSantosSRGameiroVS. (2011). The association of human primary bone cells with biphasic calcium phosphate (betaTCP/HA 70:30) granules increases bone repair. J Mater Sci Mater Med23:781-788.
39.
LuHKawazoeNKitajimaTMyokenYTomitaMUmezawaA. (2008). Spatial immobilization of bone morphogenetic protein-4 in a collagen-PLGA hybrid scaffold for enhanced osteoinductivity. Biomaterials33:6140-6146.
40.
LuoTZhangWShiBChengXZhangY (2012). Enhanced bone regeneration around dental implant with bone morphogenetic protein 2 gene and vascular endothelial growth factor protein delivery. Clin Oral Implants Res23:467-473.
41.
MitriFAlvesGFernandesGKonigBRossiAJGranjeiroJ (2012). Cytocompatibility of porous biphasic calcium phosphate granules with human mesenchymal cells by a multiparametric assay. Artif Organs36:535-542.
42.
MuellerTDNickelJ (2012). Promiscuity and specificity in BMP receptor activation. FEBS Lett586:1846-1859.
43.
NeoviusELembergerMDocherty SkoghACHilbornJEngstrandT (2013). Alveolar bone healing accompanied by severe swelling in cleft children treated with bone morphogenetic protein-2 delivered by hydrogel. J Plast Reconstr Aesthet Surg66:37-42.
44.
OhSHKimTHLeeJH (2011). Creating growth factor gradients in three dimensional porous matrix by centrifugation and surface immobilization. Biomaterials32:8254-8260.
45.
OnichtchoukDChenYGDoschRGawantkaVDeliusHMassaguéJ. (1999). Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature401:480-485.
46.
PapakostidisCKontakisGBhandariMGiannoudisPV (2008). Efficacy of autologous iliac crest bone graft and bone morphogenetic proteins for posterolateral fusion of lumbar spine: a meta-analysis of the results. Spine (Phila Pa 1976)33:E680-E692.
47.
PolimeniGKooKTPringleGAAgelanASafadiFFWikesjöUM (2008). Histopathological observations of a polylactic acid-based device intended for guided bone/tissue regeneration. Clin Implant Dent Relat Res10:99-105.
48.
RittingAWWeberEWLeeMC (2012). Exaggerated inflammatory response and bony resorption from BMP-2 use in a pediatric forearm nonunion. J Hand Surg Am37:316-321.
49.
RongaMFagettiACantonGPaiuscoESuraceMFCherubinoP (2013). Clinical applications of growth factors in bone injuries: experience with BMPs. Injury44(Suppl 1):34-39.
50.
RotenbergSATatakisDN (2011). Recombinant human bone morphogenetic protein-2 bone regeneration: a case report. J Periodontol82:1212-1218.
51.
RutherfordRBSampathTKRuegerDCTaylorTD (1992). Use of bovine osteogenic protein to promote rapid osseointegration of endosseous dental implants. Int J Oral Maxillofac Implants7:297-301.
52.
SaitoASaitoEHandaRHonmaYKawanamiM (2009). Influence of residual bone on recombinant human bone morphogenetic protein-2-induced periodontal regeneration in experimental periodontitis in dogs. J Periodontol80:961-968.
53.
SalgadoPCSathlerPCCastroHCAlvesGGOliveiraAMOliveiraRC. (2011). Bone remodeling, biomaterials and technological applications: revisiting basic concepts. J Biomater Nanobiotechnol2:318-328.
54.
SapkotaGAlarconCSpagnoliFMBrivanlouAHMassagueJ (2007). Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell25:441-454.
SigurdssonTJLeeMBKubotaKTurekTJWozneyJMWikesjöUM (1995). Periodontal repair in dogs: recombinant human bone morphogenetic protein-2 significantly enhances periodontal regeneration. J Periodontol66:131-138.
57.
SimionMRocchiettaIMonforteMMascheraE (2008). Three-dimensional alveolar bone reconstruction with a combination of recombinant human platelet-derived growth factor BB and guided bone regeneration: a case report. Int J Periodontics Restorative Dent28:239-243.
58.
UristMR (1965). Bone: formation by autoinduction. Science150:893-899.
59.
WalshG (2010). Post-translational modifications of protein biopharmaceuticals. Drug Discov Today15:773-780.
60.
WeiSCaiXHuangJXuFLiuXWangQ (2012). Recombinant human BMP-2 for the treatment of open tibial fractures. Orthopedics35(6):e847-e854.
61.
WilkinsonLKolleGWenDPiperMScottJLittleM (2003). CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. J Biol Chem278:34181-34188.
62.
WilliamsBJSmithJSFuKMHamiltonDKPollyDWJrAmesCP. (2011). Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion? A comparison of 55,862 cases of spinal fusion with and without bone morphogenetic protein. Spine (Phila Pa 1976)36:1685-1691.
63.
WinnSRUludagHHollingerJO (1999). Carrier systems for bone morphogenetic proteins. Clin Orthop Relat Res367(Suppl):95-106.
64.
WozneyJMRosenVCelesteAJMitsockLMWhittersMJKrizRW. (1988). Novel regulators of bone formation: molecular clones and activities. Science242:1528-1534.
65.
YangXHanGPangXFanM (2012). Chitosan/collagen scaffold containing bone morphogenetic protein-7 DNA supports dental pulp stem cell differentiation in vitro and in vivo. J Biomed Mater Res A [Epub ahead of print 2/18/2013] (in press).
66.
ZambuzziWFFernandesGVIanoFGFernandes MdaSGranjeiroJMOliveiraRC (2012). Exploring anorganic bovine bone granules as osteoblast carriers for bone bioengineering: a study in rat critical-size calvarial defects. Braz Dent J23:315-321.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
